Vor Biopharma (NYSE:VOR) Earns “Outperform” Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating restated by Wedbush in a research report issued to clients and investors on Thursday, Marketbeat reports.

Other equities analysts have also recently issued research reports about the stock. JMP Securities reiterated a “market perform” rating and set a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Citizens Jmp downgraded Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Friday, May 9th. Oppenheimer restated an “outperform” rating and issued a $8.00 target price on shares of Vor Biopharma in a research note on Friday, March 21st. Jones Trading cut Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Finally, Stifel Nicolaus decreased their price objective on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 21st. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.06.

Vor Biopharma Stock Performance

Shares of NYSE VOR traded up $0.20 during trading hours on Thursday, hitting $1.09. The company’s stock had a trading volume of 45,034,708 shares, compared to its average volume of 6,643,485. The stock has a market cap of $135.96 million, a price-to-earnings ratio of -0.66 and a beta of -0.51. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $1.80. The business has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.83.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Vor Biopharma during the 4th quarter valued at about $60,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $80,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma in the 4th quarter worth approximately $33,000. Lynx1 Capital Management LP bought a new position in Vor Biopharma in the 4th quarter valued at approximately $707,000. Finally, Northern Trust Corp lifted its position in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.